Tm Bioscience ready to consider sale or merger
This article was originally published in Clinica
Tm Bioscience, the Toronto-based developer of DNA-based tests, says it would consider a sale or merger of its business as part of an exploration of ways to increase its value to shareholders. The company has appointed investment banks Leerink & Swann, of Boston, Massachusetts, and Westwind Partners, of Toronto, to help assess its options.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.